188 related articles for article (PubMed ID: 38695556)
1. Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic
Kane A; Dinh H; Campbell L; Cain AK; Hibbs D; Carter D
Microbiol Spectr; 2024 Jun; 12(6):e0012124. PubMed ID: 38695556
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates synergistically enhance the antifungal activity of azoles in dermatophytes and other pathogenic molds.
Kane A; Rothwell JG; Guttentag A; Hainsworth S; Carter D
mSphere; 2024 Jun; 9(6):e0024824. PubMed ID: 38837382
[TBL] [Abstract][Full Text] [Related]
3. Small molecules restore azole activity against drug-tolerant and drug-resistant
Alabi PE; Gautier C; Murphy TP; Gu X; Lepas M; Aimanianda V; Sello JK; Ene IV
mBio; 2023 Aug; 14(4):e0047923. PubMed ID: 37326546
[TBL] [Abstract][Full Text] [Related]
4. Oxadiazole-Containing Macrocyclic Peptides Potentiate Azole Activity against Pathogenic
Revie NM; Robbins N; Whitesell L; Frost JR; Appavoo SD; Yudin AK; Cowen LE
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269162
[TBL] [Abstract][Full Text] [Related]
5. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.
Onyewu C; Blankenship JR; Del Poeta M; Heitman J
Antimicrob Agents Chemother; 2003 Mar; 47(3):956-64. PubMed ID: 12604527
[TBL] [Abstract][Full Text] [Related]
6. UPC2A is required for high-level azole antifungal resistance in Candida glabrata.
Whaley SG; Caudle KE; Vermitsky JP; Chadwick SG; Toner G; Barker KS; Gygax SE; Rogers PD
Antimicrob Agents Chemother; 2014 Aug; 58(8):4543-54. PubMed ID: 24867980
[TBL] [Abstract][Full Text] [Related]
7. The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.
Gomaa SE; Abbas HA; Mohamed FA; Ali MAM; Ibrahim TM; Abdel Halim AS; Alghamdi MA; Mansour B; Chaudhary AA; Elkelish A; Boufahja F; Hegazy WAH; Yehia FAA
BMC Microbiol; 2024 Feb; 24(1):54. PubMed ID: 38341568
[TBL] [Abstract][Full Text] [Related]
8. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
9.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
10. Milbemycins: more than efflux inhibitors for fungal pathogens.
Silva LV; Sanguinetti M; Vandeputte P; Torelli R; Rochat B; Sanglard D
Antimicrob Agents Chemother; 2013 Feb; 57(2):873-86. PubMed ID: 23208712
[TBL] [Abstract][Full Text] [Related]
11. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.
Holmes AR; Keniya MV; Ivnitski-Steele I; Monk BC; Lamping E; Sklar LA; Cannon RD
Antimicrob Agents Chemother; 2012 Mar; 56(3):1508-15. PubMed ID: 22203607
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
[TBL] [Abstract][Full Text] [Related]
13. Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.
Tantivitayakul P; Lapirattanakul J; Kaypetch R; Muadcheingka T
J Glob Antimicrob Resist; 2019 Jun; 17():221-226. PubMed ID: 30658200
[TBL] [Abstract][Full Text] [Related]
14. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
15. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
16. Upc2-mediated mechanisms of azole resistance in
Li J; Aubry L; Brandalise D; Coste AT; Sanglard D; Lamoth F
Microbiol Spectr; 2024 Feb; 12(2):e0352623. PubMed ID: 38206035
[No Abstract] [Full Text] [Related]
17. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
Zhang M; Yan H; Lu M; Wang D; Sun S
Int J Antimicrob Agents; 2020 Jan; 55(1):105804. PubMed ID: 31605727
[TBL] [Abstract][Full Text] [Related]
18. Antifungal activity and potential mechanism of Asiatic acid alone and in combination with fluconazole against Candida albicans.
Wang Y; Lu C; Zhao X; Wang D; Liu Y; Sun S
Biomed Pharmacother; 2021 Jul; 139():111568. PubMed ID: 33845374
[TBL] [Abstract][Full Text] [Related]
19. Gentamicin synergises with azoles against drug-resistant Candida albicans.
Lu M; Yu C; Cui X; Shi J; Yuan L; Sun S
Int J Antimicrob Agents; 2018 Jan; 51(1):107-114. PubMed ID: 28943366
[TBL] [Abstract][Full Text] [Related]
20. The synergistic antifungal effects of gypenosides combined with fluconazole against resistant Candida albicans via inhibiting the drug efflux and biofilm formation.
Liu Y; Ren H; Wang D; Zhang M; Sun S; Zhao Y
Biomed Pharmacother; 2020 Oct; 130():110580. PubMed ID: 32745913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
